People · Operator
Named in public records as an officer, director or promoter · active 2008–2011 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Newlink Genetics Corp | — | Biotechnology | Series B | $67.5M | $411.2M | 2008 |
Sarah J. Alexander, M.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sarah J. Alexander, M.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Paul R. Edick | 1 | 2 |
| Ernest H. Talarico, III | 1 | 1 |
| Joseph J. Saluri | 1 | 1 |
| Nicholas Vahanian, M.D. | 1 | 1 |
| Kenneth J. Lynn | 1 | 1 |
| Gordon H. Link | 1 | 1 |
| David J. Lundquist | 1 | 1 |
| Tom H. Raffin, M.D. | 1 | 1 |
| Charles Link, M.D. | 1 | 1 |
| Paul J. Edick | 1 | 1 |
| Kenneth Lynn | 1 | 1 |
| Ernest Talarico, III | 1 | 1 |
| Tom Raffin, M.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.